Pengxun Han
- Molecular Biology
- Nephrology top 10%
- Physiology
- Epidemiology
- Clinical Biochemistry top 10%
- Topics
- Chronic Kidney Disease and Diabetes (8 papers)Mitochondrial Function and Pathology (5 papers)Renal Diseases and Glomerulopathies (4 papers)
- Partner nations
- ChinaUnited States
In The Last Decade
Pengxun Han
22 papers receiving 391 citations
Peers
Comparison fields: 5 of 71
- Molecular Biology 202
- Nephrology 84
- Physiology 72
- Epidemiology 71
- Clinical Biochemistry 53
Countries citing papers authored by Pengxun Han
This map shows the geographic impact of Pengxun Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pengxun Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pengxun Han more than expected).
Fields of papers citing papers by Pengxun Han
This network shows the impact of papers produced by Pengxun Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pengxun Han. The network helps show where Pengxun Han may publish in the future.
Co-authorship network of co-authors of Pengxun Han
This figure shows the co-authorship network connecting the top 25 collaborators of Pengxun Han. A scholar is included among the top collaborators of Pengxun Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pengxun Han. Pengxun Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 10 | |
| 3 | 4 | |
| 4 | Artemether attenuates renal tubular injury by regulating iron metabolism in mice with streptozotocin-induced diabetes. | 1 |
| 5 | Artemether attenuates renal tubular injury by targeting mitochondria in adriamycin nephropathy mice. | 4 |
| 6 | 14 | |
| 7 | 2 | |
| 8 | Combination of astragaloside IV and ACEi ameliorates renal injuries in db/db mice. | 6 |
| 9 | Niclosamide ethanolamine attenuates systemic lupus erythematosus and lupus nephritis in MRL/lpr mice. | 8 |
| 10 | Niclosamide ethanolamine protects kidney in adriamycin nephropathy by regulating mitochondrial redox balance. | 12 |
| 11 | Artemether improves type 1 diabetic kidney disease by regulating mitochondrial function. | 17 |
| 12 | Artemether ameliorates type 2 diabetic kidney disease by increasing mitochondrial pyruvate carrier content in db/db mice. | 27 |
| 13 | 22 | |
| 14 | Renalase overexpression in ER-positive breast cancer. | 6 |
| 15 | 28 | |
| 16 | Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice. | 19 |
| 17 | 88 | |
| 18 | 61 | |
| 19 | 50 | |
| 20 | 10 |
About Pengxun Han
Pengxun Han is a scholar working on Nephrology, Clinical Biochemistry and Complementary and alternative medicine, having authored 22 papers that have together received 392 indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (8 papers), Mitochondrial Function and Pathology (5 papers) and Renal Diseases and Glomerulopathies (4 papers). The work is most often cited by research in Nephrology (84 citations), Clinical Biochemistry (53 citations) and Geriatrics and Gerontology (23 citations). Pengxun Han has collaborated with scholars based in China and United States. Frequent co-authors include Huili Sun, Mumin Shao, Shunmin Li, Dongtao Wang, Xuewen Yu, Tiegang Yi, Wenjing Wang, Yajun Yang, Shunmin Li and Heng Du. Their work appears in journals such as PLoS ONE, Scientific Reports and BioMed Research International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.